Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Cheng‐Yu Liao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7221-7522; OpenAlex author ID A5002419965. Sources: OpenAlex.

Their work

Papers
16 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: none · 2024: 4 papers · 2025: 5 papers · 2026: 1 paper

Papers 16

  1. Hypertemperature-Detonated Biomimetic Semiconductor Stromal Bombs for Enhanced Immunotherapy in Pancreatic Cancer. Co-author DOI 10.1002/adma.202523468↗
  2. SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202508431↗
  3. Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer. Co-author DOI 10.1016/j.drup.2025.101240↗
  4. Targeting CLK1/SRSF7 axis-dependent alternative splicing sensitizes pancreatic ductal adenocarcinoma to chemotherapy and immunotherapy. Co-author DOI 10.1016/j.drup.2025.101292↗
  5. KRT7 promotes pancreatic cancer metastasis by remodeling the extracellular matrix niche through FGF2-fibroblast crosstalk. First author DOI 10.1038/s41598-024-84129-1↗
  6. TRAF3IP2-AS1 Deficiency Induces Necroptosis to Promote Pancreatic Cancer Liver Metastasis. Co-author DOI 10.1158/0008-5472.can-24-4784↗
  7. Targeting the MCP-GPX4/HMGB1 Axis for Effectively Triggering Immunogenic Ferroptosis in Pancreatic Ductal Adenocarcinoma. First author DOI 10.1002/advs.202308208↗
  8. cNEK6 induces gemcitabine resistance by promoting glycolysis in pancreatic ductal adenocarcinoma via the SNRPA/PPA2c/mTORC1 axis. Co-author DOI 10.1038/s41419-024-07138-y↗
  9. Necroptosis enhances 'don't eat me' signal and induces macrophage extracellular traps to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s41467-024-50450-6↗
  10. Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. First author DOI 10.1186/s12943-024-02128-2↗
  11. SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine. Co-author DOI 10.1016/j.celrep.2022.110813↗
  12. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-022-02343-z↗
  13. SHCBP1 interacting with EOGT enhances O-GlcNAcylation of NOTCH1 and promotes the development of pancreatic cancer. Co-author DOI 10.1016/j.ygeno.2021.01.010↗
  14. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s13045-021-01072-8↗
  15. Construction and Validation of Novel Nomograms for Predicting Prognosis of Pancreatic Ductal Adenocarcinoma After Surgery According to Different Primary Cancer… First author DOI 10.3389/fonc.2021.646082↗
  16. SHCBP1 interacting with EOGT enhanced O-GlcNAcylation of NOTCH1 and promoted the development of pancreatic cancer . Co-author DOI 10.21203/rs.3.rs-95104/v1↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shi Chen · 15 shared papers, 2020–2026 · strength 2.48
  2. Zuwei Wang · 13 shared papers, 2020–2025 · strength 2.14
  3. Shun‐Cang Zhu · 7 shared papers, 2024–2025 · strength 1.34
  4. Yifeng Tian · 9 shared papers, 2020–2026 · strength 1.34
  5. Yongding Wu · 6 shared papers, 2024–2025 · strength 1.16
  6. Chengke Xie · 6 shared papers, 2024–2025 · strength 1.14
  7. Ge Li · 4 shared papers, 2024–2025 · strength 0.78
  8. Hong-Yi Lin · 4 shared papers, 2024–2025 · strength 0.77
  9. Long Huang · 5 shared papers, 2020–2022 · strength 0.61
  10. Haoxiang Zhang · 3 shared papers, 2025 · strength 0.60
  11. Can Yang · 5 shared papers, 2020–2022 · strength 0.58
  12. Ge Li · 3 shared papers, 2021–2025 · strength 0.51
  13. Baiyong Shen · 4 shared papers, 2020–2022 · strength 0.46
  14. Qian Zhan · 4 shared papers, 2020–2021 · strength 0.45
  15. Yu Pan · 2 shared papers, 2025 · strength 0.40
  16. Yanling Chen · 2 shared papers, 2021–2024 · strength 0.31
  17. Xiaoling Zheng · 1 shared paper, 2025 · strength 0.30
  18. Yuting Jiang · 1 shared paper, 2025 · strength 0.30
  19. Yaodong Wang · 2 shared papers, 2021–2022 · strength 0.25
  20. Chengke Xie · 1 shared paper, 2026 · strength 0.22
  21. Chun Zhang · 1 shared paper, 2025 · strength 0.20
  22. Jiangzhi Chen · 1 shared paper, 2024 · strength 0.18
  23. Yanling Chen · 1 shared paper, 2024 · strength 0.18
  24. Huixing Chen · 1 shared paper, 2024 · strength 0.18
  25. Zhi‐Wen Chen · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.